Fortress Biotech's $205M Voucher Sale Signals Path to Profitability

MIAMI, FL – February 23, 2026 – Fortress Biotech and its subsidiary Cyprium Therapeutics have executed a significant financial maneuver, agreeing to sell a highly coveted regulatory asset for $205 million. The deal, announced today, involves a Rare Pediatric Disease Priority Review Voucher (PRV) being sold to Sentynl Therapeutics, the same company commercializing the drug that earned the voucher in the first place.

This transaction provides a massive infusion of non-dilutive capital for Fortress and Cyprium, validating the company's long-term strategy of developing treatments for rare diseases. The PRV was awarded by the U.S. Food and Drug Administration (FDA) just last month following the landmark approval of ZYCUBO, the first-ever treatment for the rare and devastating Menkes disease. For Fortress, the sale is a critical step in a series of strategic wins that its leadership believes will steer the biopharmaceutical company to profitability this year.

The Soaring Value of FDA Vouchers

The centerpiece of the deal, the Priority Review Voucher, represents a valuable tradable asset in the biopharmaceutical industry. These vouchers are granted by the FDA as an incentive for companies to develop drugs for rare pediatric or tropical diseases that might otherwise be neglected. The holder of a PRV can redeem it to shorten the FDA's review time for a different drug from the standard ten months to an expedited six months. For a potential blockbuster drug, shaving four months off the path to market can translate into hundreds of millions of dollars in additional revenue.

The $205 million price tag for Cyprium's voucher underscores a heating market for these assets. The sale price is a notable increase from the typical range of $150 million to $175 million seen in transactions during 2025. It closely follows a recent precedent set only a month ago when Jazz Pharmaceuticals sold a similar voucher for $200 million, signaling strong demand and rising valuations. The buyer, Sentynl Therapeutics, is already deeply involved with the underlying asset, having assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium in December 2023. By purchasing the PRV, Sentynl gains a strategic tool to accelerate one of its own future pipeline products.

A Financial Windfall and Strategic Execution

The $205 million in gross proceeds triggers a cascade of financial benefits for Fortress Biotech and its stakeholders. Per its agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which collaborated on the drug's development, Cyprium will pay 20% of the proceeds, or $41 million, to the NIH institute. This leaves approximately $164 million in net proceeds for Cyprium before taxes and other obligations.

Fortress Biotech, which holds an 80.4% majority stake in Cyprium, expects to receive at least $100 million of this windfall over time through dividends and other intercompany arrangements. This capital injection significantly strengthens Fortress's balance sheet and provides substantial flexibility to advance its broad pipeline of clinical-stage assets. The company has already amended its credit facility, using the deal's finalization to ease certain covenants and make a required $10 million debt prepayment.

In a statement, Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, framed the sale as a continuation of successful strategy. “The recent approval of ZYCUBO was a significant achievement for patients with Menkes disease and the sale of the PRV by Cyprium shows our continued execution in value-generating corporate transactions,” he said. “With the PRV sale and three FDA approvals received in the last 15 months for Emrosi™, UNLOXCYT™, and ZYCUBO, in addition to the recent sale of our former subsidiary Checkpoint Therapeutics to Sun Pharma, we believe that we are well positioned to reach profitability this year.”

Behind the Deal: A Breakthrough for Menkes Disease

Beyond the nine-figure price tag, the transaction is rooted in a major medical breakthrough for one of the world's rarest diseases. Menkes disease is a fatal X-linked recessive disorder caused by a mutation in the ATP7A gene. The mutation impairs the body's ability to transport copper, leading to severe copper deficiency in the brain and other tissues, which results in rapid neurodegeneration, seizures, and developmental failure in affected infants, who rarely survive past early childhood.

Until this year, there were no FDA-approved treatments. The approval of ZYCUBO (copper histidinate) on January 12, 2026, marked a pivotal moment for patients and families affected by the condition, offering the first and only approved therapy in the United States. The PRV sale is a direct consequence of this success, representing the financial reward intended by the FDA's incentive program.

Cyprium's work on Menkes disease is not over. The company continues its collaboration with the NICHD on a next-generation treatment: an adeno-associated virus (AAV)-based gene therapy. This therapy, currently in preclinical development, is designed to deliver a working copy of the defective ATP7A gene. “We are deeply grateful for everyone's support and look forward to advancing AAV-ATP7A Gene Therapy toward clinical development to provide additional therapeutic options for patients with Menkes disease,” said Lung S. Yam, M.D., Ph.D., Cyprium’s President and Chief Executive Officer.

Cyprium also remains financially tied to ZYCUBO's commercial success, standing to receive tiered royalties on net sales and up to $129 million in future development and sales milestones from Sentynl. This ensures a continued revenue stream that will help fund its future research endeavors, including the promising gene therapy program. The successful development and monetization cycle of ZYCUBO serves as a powerful example of how incentivizing rare disease research can yield both profound patient benefits and significant financial returns for the companies willing to take on the challenge.